Collecting data on cellular immunotherapy for lymphoma patients
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
This study is gathering information from adults with relapsed or hard-to-treat non-Hodgkin's lymphoma who are getting cellular immunotherapy to see how well it works and how safe it is.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Drugs / interventions | CAR-T, chimeric antigen receptor, immunotherapy |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06541327 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather clinical data from adult patients with relapsed or refractory non-Hodgkin's lymphoma who are receiving cellular immunotherapy. The study will collect efficacy and safety data over a period from January 2017 to December 2040, focusing on various types of cellular immunotherapy treatments. Investigators will analyze the data to determine optimal diagnostic and treatment plans based on clinical practice, without any intervention from the study itself. Data will be collected at multiple time points, including before treatment, on the day of infusion, and during follow-up visits within 24 months post-infusion.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients with a confirmed diagnosis of relapsed or refractory non-Hodgkin's lymphoma who have received or are receiving cellular immunotherapy.
Not a fit: Patients who do not have a diagnosis of relapsed or refractory non-Hodgkin's lymphoma or who have not received cellular immunotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cellular immunotherapy's effectiveness and safety for lymphoma patients, potentially leading to improved treatment strategies.
How similar studies have performed: Other studies on cellular immunotherapy have shown promising results, indicating that this approach is gaining traction in the treatment of lymphoma.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with a confirmed diagnosis of r/r B-NHL (including r/r DLBCL, r/r FL, r/r MCL, HGBL-NOS, FL3b, r/r MZL, transformed lymphomas such as MCL) and r/r T-cell lymphoma, who have received informed consent waivers; * Patients who have received or are receiving cellular immunotherapy, with cellular immunotherapy products including the following categories: cytokine-induced killer cell therapy (CIK), tumor-infiltrating lymphocytes (TIL), cytokine-induced killer cell-dendritic cell mixed therapy (DC-CIK), chimeric antigen receptor T cells, NK cells or macrophage therapy (CAR-T, CAR-NK, CAR-M), T-cell receptor chimeric T cell therapy (TCR-T), dendritic cell therapy. Exclusion Criteria: * NA
Where this trial is running
Shanghai
- Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Weili Zhao
- Email: zwl_trial@163.com
- Phone: +862164370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.